---
schema_version: "secwatch.filing_event.v1"
accession: "0001161697-25-000168"
form_type: "8-K"
ticker: "KRMD"
cik: "0000704440"
company_name: "KORU Medical Systems, Inc."
filed_at: "2025-05-07T23:59:59+00:00"
generated_at: "2026-05-22T09:43:32.966054+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# KORU Medical reports record Q1 revenue of $9.6M, up 18% YoY; raises FY2025 guidance

## Summary
- Core revenue (Domestic + International) grew 21% YoY to $9.4M; International up 35.6%.
- Gross margin improved 50 bps to 62.8%; gross profit $6.0M, up 19%.
- Net loss narrowed; adjusted EBITDA improved to ($0.2M) from ($0.9M) prior year.
- FY2025 revenue guidance raised to $38.5-39.5M from $38-39M; gross margin guidance reiterated at 61-63%.
- Plans to submit two drugs for FDA 510(k) clearance with Freedom Infusion System by year-end.

## SEC filing metadata
- accession: 0001161697-25-000168
- form_type: 8-K
- ticker: KRMD
- cik: 0000704440
- company_name: KORU Medical Systems, Inc.
- filed_at: 2025-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/704440/000116169725000168/0001161697-25-000168-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/704440/000116169725000168/form_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001161697-25-000168
- JSON: https://secwatch.observer/filing/0001161697-25-000168.json
- Plain text: https://secwatch.observer/filing/0001161697-25-000168.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.